title: Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.
authors.affiliation: Division of Cancer Treatment and Diagnostics, National Cancer Institute, Bethesda, Maryland 20892, USA. kelloffg@mail.nih.gov
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Kelloff
authors.forename: Donald S
authors.initials: DS
authors.lastname: Coffey
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Chabner
authors.forename: Adam P
authors.initials: AP
authors.lastname: Dicker
authors.forename: Kathryn Z
authors.initials: KZ
authors.lastname: Guyton
authors.forename: Perry D
authors.initials: PD
authors.lastname: Nisen
authors.forename: Howard R
authors.initials: HR
authors.lastname: Soule
authors.forename: Anthony V
authors.initials: AV
authors.lastname: D'Amico
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D015195:Drug Design; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000096:biosynthesis*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy*; D012107:Research Design; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen